NPP1-Containing Polypeptides for PPi-Mediated Vascular Calcification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for diseases associated with pathological calcification and ossification, such as Generalized Arterial Calcification of Infancy (GACI) and Pseudoxanthoma elasticum (PXE), are ineffective and can cause severe side effects, and there is a need for compositions and methods that do not disrupt other physiological processes.

Innovation Solution

The use of NPP1-containing polypeptides, such as those with an IgG Fc domain or human serum albumin, to increase extracellular pyrophosphate (PPi) concentrations, thereby inhibiting calcification by targeting ectopic mineralization.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If bisphosphonates are used to treat GACI, then mortality rate decreases, but severe skeletal toxicity occurs

Engineering Contradiction:

Improvemortality rateVSAvoidskeletal toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses pyrophosphate (PPi) as an intermediary substance that specifically targets ectopic calcification in blood vessels without affecting bone metabolism. PPi acts as a selective inhibitor of hydroxyapatite crystal growth in vascular tissues while leaving bone formation processes intact, thereby resolving the contradiction between reducing mortality and avoiding skeletal toxicity.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention applies local quality by directing pyrophosphate action specifically to pathological calcification sites in blood vessels through targeted administration strategies. The treatment achieves high concentration of PPi at the vascular calcification sites while maintaining normal physiological levels in bone tissues, thus providing localized therapeutic effect without systemic skeletal side effects.

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If pyrophosphate levels are increased to inhibit calcification, then ectopic mineralization is prevented, but other physiological processes may be disrupted

Engineering Contradiction:

Improveectopic mineralizationVSAvoidphysiological process disruption

Core Design Contradiction:

Object-affected harmful factorsVSAdaptability or versatility

Solution Approach 1:

The patent applies partial action by administering pyrophosphate at doses and concentrations specifically calibrated to inhibit ectopic vascular calcification while maintaining physiological PPi levels in other tissues. The treatment achieves sufficient PPi concentration at calcification sites to prevent mineralization without exceeding thresholds that would disrupt normal physiological processes in other organ systems.

Inventive Principle:

Principle #16Partial or excessive action

3Reliability

If current treatments are applied to prevent calcification, then some calcification progression is halted, but treatment effectiveness is limited and side effects occur

Engineering Contradiction:

Improvecalcification preventionVSAvoidtreatment side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the naturally occurring substance pyrophosphate, which is already present in the body at physiological levels, into a therapeutic agent. By administering endogenous PPi at elevated but controlled levels, the treatment leverages a naturally compatible molecule to prevent calcification, thereby reducing immunogenicity and side effects compared to synthetic inhibitors, while converting the body's own defense mechanism into an effective therapy.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively reduces or prevents cardiac and arterial calcifications, improving survival and health outcomes in affected infants and patients by stabilizing PPi levels, thus mitigating the progression of diseases like GACI and PXE.

Implementation Method 1

ENPP1 (also known as NPP1 or PC-1) is a member of the ectonucleotide pyrophosphatase/phosphodiesterase (also known as ENPP or NPP) family of enzymes, which are characterized by phosphodiesterase activity

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Implementation Method 2

ENPP1 catabolizes the degradation of extracellular ATP into AMP and PPi

Methodology Applied

Scientific EffectHydrolysis: Hydrolysis

Implementation Method 3

PPi inhibits ectopic tissue mineralization, presumably by occupying some of the Pi sites on the surface of nascent or growing hydroxyapatite (HA) crystals, thereby creating irregularities that slow or terminate the propagation of crystal growth

Methodology Applied

Scientific EffectCrystal growth inhibition: Crystallisation

Data Source

PatentUS20250295733A1Compositions for Treating Pathological Calcification Conditions, and Methods Using Same

Publication Date: 2025.09.25 YALE UNIVERSITY

AI summary

The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.